Quintin J.  Lai net worth and biography

Quintin Lai Biography and Net Worth

Dr. Quintin J. Lai Ph.D. serves as Vice President - Corporate Development, Strategy and Investor Relations of the Company. Prior to joining West, he was Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation from 2012 to 2015. From 2002 to 2012, he was at Robert W. Baird & Company, where he held various roles, including Managing Director and Senior Equity Research Analyst of the Life Science Tools and Diagnostic sector and Associate Director of Equity Research.

What is Quintin J. Lai's net worth?

The estimated net worth of Quintin J. Lai is at least $6.81 million as of August 11th, 2023. Dr. Lai owns 18,307 shares of West Pharmaceutical Services stock worth more than $6,811,302 as of April 20th. This net worth approximation does not reflect any other investments that Dr. Lai may own. Learn More about Quintin J. Lai's net worth.

How old is Quintin J. Lai?

Dr. Lai is currently 57 years old. There are 7 older executives and no younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services is Ms. Annette F. Favorite, Chief Human Resources Officer & Senior VP, who is 59 years old. Learn More on Quintin J. Lai's age.

How do I contact Quintin J. Lai?

The corporate mailing address for Dr. Lai and other West Pharmaceutical Services executives is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. West Pharmaceutical Services can also be reached via phone at (610) 594-2900 and via email at [email protected]. Learn More on Quintin J. Lai's contact information.

Has Quintin J. Lai been buying or selling shares of West Pharmaceutical Services?

Quintin J. Lai has not been actively trading shares of West Pharmaceutical Services over the course of the past ninety days. Most recently, Quintin J. Lai sold 21,101 shares of the business's stock in a transaction on Friday, August 11th. The shares were sold at an average price of $395.12, for a transaction totalling $8,337,427.12. Following the completion of the sale, the vice president now directly owns 18,307 shares of the company's stock, valued at $7,233,461.84. Learn More on Quintin J. Lai's trading history.

Who are West Pharmaceutical Services' active insiders?

West Pharmaceutical Services' insider roster includes Silji Abraham (Insider), Bernard Birkett (SVP), Annette Favorite (VP), Eric Green (CEO), Thomas Hofmann (Director), Quintin Lai (VP), George Miller (VP), Cindy Reiss-Clark (Insider), Chad Winters (CAO), and Patrick Zenner (Director). Learn More on West Pharmaceutical Services' active insiders.

Are insiders buying or selling shares of West Pharmaceutical Services?

In the last twelve months, insiders at the medical instruments supplier sold shares 17 times. They sold a total of 202,177 shares worth more than $74,559,298.70. The most recent insider tranaction occured on March, 11th when CAO Chad Winters sold 815 shares worth more than $292,438.30. Insiders at West Pharmaceutical Services own 0.5% of the company. Learn More about insider trades at West Pharmaceutical Services.

Information on this page was last updated on 3/11/2024.

Quintin J. Lai Insider Trading History at West Pharmaceutical Services

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2023Sell21,101$395.12$8,337,427.1218,307View SEC Filing Icon  
3/14/2022Sell8,016$371.69$2,979,467.04View SEC Filing Icon  
9/10/2021Sell9,672$460.76$4,456,470.72View SEC Filing Icon  
See Full Table

Quintin J. Lai Buying and Selling Activity at West Pharmaceutical Services

This chart shows Quintin J Lai's buying and selling at West Pharmaceutical Services by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

West Pharmaceutical Services Company Overview

West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $372.06
Low: $371.88
High: $379.12

50 Day Range

MA: $378.56
Low: $350.18
High: $408.19

2 Week Range

Now: $372.06
Low: $310.42
High: $415.73

Volume

444,740 shs

Average Volume

314,853 shs

Market Capitalization

$27.24 billion

P/E Ratio

47.22

Dividend Yield

0.21%

Beta

1.04